Autolus Therapeutics Announced The Pricing Of An Underwritten Offering In The United States Of 58,333,336 American Depositary Shares (ADSs) Representing 58,333,336 Ordinary Shares At A $6.00 Per ADS, For Total Gross Proceeds Of $350M
Portfolio Pulse from Benzinga Newsdesk
Autolus Therapeutics has priced an underwritten offering in the U.S. of 58,333,336 ADSs at $6.00 each, aiming for total gross proceeds of $350M.
February 08, 2024 | 12:05 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Autolus Therapeutics aims to raise $350M through an offering of 58,333,336 ADSs at $6.00 each.
The announcement of an underwritten offering is a common equity action for companies seeking to raise capital. While this increases the company's cash reserves, it also dilutes existing shareholders' equity. The impact on the stock price can be neutral in the short term as the benefits of increased capital might balance out the dilution effect.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100